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Abstract. 
 
The tumor suppressor PTEN dephosphory-
lates focal adhesion kinase (FAK) and inhibits integrin-
mediated cell spreading and cell migration. We demon-
strate here that expression of PTEN selectively inhibits 
activation of the extracellular signal-regulated kinase 
(ERK) mitogen-activated protein kinase (MAPK) 
pathway. PTEN expression in glioblastoma cells lack-
ing the protein resulted in inhibition of integrin-medi-
ated MAP kinase activation. Epidermal growth factor 
(EGF) and platelet-derived growth factor (PDGF)-
induced MAPK activation were also blocked. To deter-
mine the specific point of inhibition in the Ras/Raf/
MEK/ERK pathway, we examined these components 
after stimulation by fibronectin or growth factors. Shc 
phosphorylation and Ras activity were inhibited by ex-
pression of PTEN, whereas EGF receptor autophos-
phorylation was unaffected. The ability of cells to 
spread at normal rates was partially rescued by coex-
pression of constitutively activated MEK1, a down-
stream component of the pathway. In addition, focal 
contact formation was enhanced as indicated by paxil-
lin staining. The phosphatase domain of PTEN was es-
sential for all of these functions, because PTEN with an 
inactive phosphatase domain did not suppress MAP ki-
nase or Ras activity. In contrast to its effects on ERK, 
 
PTEN expression did not affect c-Jun NH
 
2
 
-terminal ki-
nase (JNK) or PDGF-stimulated Akt. Our data suggest 
that a general function of PTEN is to down-regulate 
FAK and Shc phosphorylation, Ras activity, down-
stream MAP kinase activation, and associated focal 
contact formation and cell spreading.
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P
 
TEN
 
 is a recently identified tumor suppressor gene
that is a dual specificity phosphatase. The PTEN
 
gene also has an NH
 
2
 
-terminal domain with exten-
sive homology to tensin, a protein that interacts with actin
filaments at focal adhesions. Deletions and mutations
within the PTEN gene have been observed in multiple
forms of human cancer, including brain, breast, prostate,
and other advanced malignancies (Kong et al., 1997; Li
et al., 1997; Steck et al., 1997). In addition, germ-line PTEN
mutations have been detected in two autosomal-dominant
disorders, Cowden disease, which confers an elevated risk
for tumors of the breast and thyroid, and Bannayan-
Zonana syndrome, which is characterized by hamartomas
and increased susceptibility to breast and thyroid cancer
(Liaw et al., 1997; Marsh et al., 1997).
PTEN encodes the catalytic motif of protein tyrosine
phosphatases, and is able to dephosphorylate serine, thre-
onine and tyrosine residues; it is thus considered a dual-
specificity phosphatase (Myers et al., 1997). Recent data
indicate that an intact catalytic phosphatase domain is es-
sential for the known functions of PTEN. For example,
wild-type PTEN has growth suppressor activity in glioma
cells, but mutated PTEN with inactivated phosphatase ac-
tivity does not (Furnari et al., 1997, and our own unpub-
lished data). We recently found that PTEN can dephos-
phorylate focal adhesion kinase (FAK)
 
1
 
 in vitro and in
vivo, and inhibits cell spreading and cell migration on ex-
tracellular matrix proteins such as fibronectin (FN) and
vitronectin (Tamura et al., 1998). Based on these observa-
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Abbreviations used in this paper:
 
 ERK, extracellular signal-related ki-
nase; FAK, focal adhesion kinase; FN, fibronectin; GFP, green fluorescent
protein; HA, hemagglutinin; JNK/SAPK, c-jun NH
 
2
 
-terminal kinase/
stress-activated protein kinase; MAP, mitogen-activated protein; MEK,
MAP or ERK kinase.
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tions, we wondered whether PTEN might affect integrin-
mediated signal transduction pathways.
The interaction of cells with the extracellular matrix via
cell surface integrins generates a series of complex signal-
ing events that serve to regulate several aspects of cell be-
havior, including growth, differentiation, adhesion, and
motility (Hynes, 1992; Yamada and Miyamoto, 1995; Ruos-
lahti and Vaheri, 1997; Schwartz, 1997). Intensive studies
have showed that integrin ligation can trigger activation of
certain MAP kinases, especially extracellular signal-regu-
lated kinase (ERK) members (Chen et al., 1994; Schlaep-
fer et al., 1994; Morino et al., 1995; Miyamoto et al., 1996).
Subsequent apparently conflicting studies have reported
that FAK is involved in integrin-triggered ERK signaling
(Schlaepfer et al., 1994; Schlaepfer and Hunter, 1997), or is
not involved (Lin et al., 1997; Wary et al., 1998) and that
Ras is required (Clark and Hynes, 1996; Schlaepfer and
Hunter, 1997) or that is not required (Chen et al., 1996) for
integrin-mediated MAP kinase activation.
On the other hand, activation of growth factor receptors
such as EGF receptor is well-known to stimulate nucle-
otide exchange on the Ras protein, which participates in
activation of the Raf family, which then sequentially phos-
phorylates and activates the downstream components
MAP or ERK kinase 1/2 (MEK1/2) and ERK1/2 (Jelinek
et al., 1996; Renshaw et al., 1997). Other types of MAP ki-
nases have distinct pathways and functions. For example,
c-Jun NH
 
2
 
-terminal kinase/stress-activated protein kinase
(JNK/SAPK) is not activated by EGF receptors, but it can
be activated by integrin clustering (Miyamoto et al., 1996),
or by treatment of cells with inflammatory cytokines or
stresses such as UV irradiation (Derijard et al., 1994).
Integrins can collaborate or synergize functionally with
growth factors in a variety of biological processes, includ-
ing cell growth and differentiation (Schwartz et al., 1995).
Among other mechanisms, integrin-growth factor synergy
or collaboration can involve the MAP kinase pathway,
e.g., associated with altered EGF receptor and PDGF re-
ceptor phosphorylation (Miyamoto et al., 1996).
Since integrins and growth factors can each separately
stimulate this pathway or function collaboratively, and
since the MAP kinase pathway has been implicated as a
regulator of such a wide variety of effects on cell growth
and differentiation, in the present study we tested whether
the tumor suppressor PTEN affects this central signaling
pathway. It has already been shown in Meyers et al. (1997)
that isolated PTEN cannot dephosphorylate ERK2 in
vitro. Nevertheless, there are a variety of upstream steps
necessary for MAP kinase activation that might be targets
of PTEN. We have therefore searched for effects of PTEN
on activities or phosphorylation levels of several compo-
nents of the Ras/ERK signal transduction pathway, and
have found that reconstitution of expression of PTEN in a
cell line devoid of this protein due to mutation markedly
inhibited Ras/ERK pathway activation in response to
stimulation by fibronectin or growth factors. Furthermore,
this inhibition by PTEN acted on Shc phosphorylation and
Ras activation, but not at the level of EGF receptor phos-
phorylation induced by EGF.
To test a biological function of MAP kinase in these
glioma cells, we cotransfected PTEN with constitutively
activated MEK1. We found that the resultant MAP kinase
 
activation could antagonize PTEN function and partially
rescue cell spreading on fibronectin impaired by PTEN.
We conclude that PTEN inhibits Ras activity, and then the
Ras/ERK common MAP kinase pathway for integrin- and
growth factorÐmediated signaling, and finally alters cell
behavior.
 
Materials and Methods
 
Reagents and Antibodies
 
EGF and platelet-derived growth factor-BB (PDGF-BB) and myelin ba-
sic protein (MBP) were purchased from Sigma Chemical Co. (St. Louis,
MO). Polyethyleneimine-F (PEI-F) cellulose was obtained from VWR
Scientific Products (Willard, OH). Enhanced chemiluminescence (ECL)
Western blotting detection reagents and 
 
32
 
P-phosphate were from Amer-
sham Life Science, Inc. (Arlington Heights, IL). Monoclonal anti-H-Ras,
anti-phospho-JNK and anti-Shc, as well as polyclonal anti-EGF receptor,
anti-Grb2 and anti-Shc antibodies were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Monoclonal anti-phospho-p44/p42 MAP ki-
nase antibody and p44/42 MAP kinase assay kits, as well as polyclonal
anti-phospho-MEK1, anti-phospho-Akt, and anti-Akt were purchased
from New England BioLabs, Inc. (Beverly, MA). Monoclonal anti-
hemagglutinin (HA) antibody was purchased from Berkeley Antibody
Co. (Richmond, CA). Monoclonal anti-paxillin, anti-FAK, and anti-phos-
photyrosine antibodies (RC20) were obtained from Transduction Labora-
tories (Lexington, KY). Cy-3Ðconjugated goat antibody to mouse immu-
noglobulin G (Jackson ImmunoResearch Laboratories, West Grove, PA)
were used at 1/600 dilution. Culture medium and FBS were provided by
GIBCO BRL (Gaithersburg, MD).
 
Plasmids
 
Green fluorescent protein (GFP) expression plasmid pGZ21
 
d
 
xZ con-
tained GFP with a Kozak consensus sequence in a cytomegalovirus
(CMV) promoter-based expression system (Tamura et al., 1998). GFP-
PTEN was generated by inserting a full-length human PTEN cDNA seg-
ment digested with HindIII and Xbal (Li et al., 1997) into the pGZ21
 
d
 
xZ
plasmid. GFP-PTEN point mutant C124A (Cys124
 
®
 
Ala) was generated
by site-directed mutagenesis using PCR as described (Tamura et al.,
1998). Plasmids containing HA-ERK2 and HA-JNK1, as well as constitu-
tively activated H-RasV12 pcDNA3 were gifts from Dr. J.S. Gutkind
(Oral and Pharyngeal Cancer Branch, NIDR, NIH, Bethesda, MD), and
three plasmids containing pMCL
 
^
 
HA-tagged MEK1 (wild-type, domi-
nant-negative, and constitutively activated) were provided by Dr. N.G.
Ahn (Department of Chemistry and Biochemistry, University of Colo-
rado, Boulder, CO; Mansour et al., 1994). Puromycin-resistance plasmid
pHA262pur was obtained from Dr. Hein te Riele (Division of Molecular
Carcinogenesis, The Netherlands Cancer Institute, The Netherlands;
Lacalle et al., 1989).
 
Cell Culture and Transfections
 
The PTEN mutated glioblastoma cell lines U-87MG, DBTRG-05MG and
U-373MG were obtained from American Type Culture Collection (Rock-
ville, MD). U-87MG cells were maintained in DME containing 10% FBS
in a humidified atmosphere containing 10% CO
 
2
 
 at 37
 
8
 
C. DBTRG-05MG
and U-373MG cells were cultured in RPMI medium 1640 and MEM, re-
spectively, with 10% FBS in a humidified atmosphere containing 5% CO
 
2
 
at 37
 
8
 
C. Electroporation of cells was performed as previously described
(LaFlamme et al., 1994) at 170 V and 960 
 
m
 
F with a Gene Pulser (Bio-Rad
Laboratories, Hercules, CA). To increase expression of transfected genes,
5 mM sodium butyrate was included in culture media. Equal transfection
efficiencies of GFP and GFP-PTEN (e.g., 42 
 
6
 
 3% and 40 
 
6
 
 5%, respec-
tively) were confirmed by fluorescence microscopy to determine percentages
of GFP-positive cells using a Zeiss Axiophot (Oberkochen, Germany).
 
Cell Adhesion and Preparation of Cell Lysates
 
24 h after transfection, cells were washed three times with PBS and then
cultured in media containing 0.2% FBS overnight. For growth factor or
FBS stimulation experiments, EGF or PDGF (10 ng/ml final concentra-
tion) or FBS (10% final concentration) were added to the culture me- 
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dium, and incubated for another 10 min. The cells were then washed once
with cold PBS and homogenized with 1% Triton X-100 lysis buffer (20 mM
Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium
pyrophosphate, 1 mM 
 
b
 
-glycerophosphate, 1 mM sodium vanadate, 10
 
m
 
g/ml leupeptin, 10 
 
m
 
g/ml aprotinin, and 1 mM phenylmethylsulfonyl flu-
oride) for analysis of protein tyrosine phosphorylation. For cell adhesion
experiments, cells were washed with PBS and detached by treating with
0.05% trypsin-EDTA. Trypsin was inactivated with 1 mg/ml soybean
trypsin inhibitor. The suspended cells were washed two times in DME
with 1% BSA. Cell suspensions were incubated in DME without serum
with 1% BSA at 37
 
8
 
C for 30 min on a rotator. Thereafter, cells were
counted and plated on dishes or glass coverslips coated with fibronectin
(10 
 
m
 
g/ml), and then incubated at 37
 
8
 
C for the indicated times in DME
with 1% BSA. The adherent cells were washed and lysed as described
above.
 
Immunoprecipitation and Immunoblotting
 
Cell lysates were incubated with primary antibodies (3 
 
m
 
g/ml) for 4 h at
4
 
8
 
C with gentle rocking. The mixtures were further incubated with Gam-
maBindG Sepharose beads for 2 h at 4
 
8
 
C. Thereafter, beads were washed
three times with lysis buffer to remove unbound proteins. Immunocom-
plexes were suspended in reducing sample buffer, heated to 100
 
8
 
C for 5
min, and then subjected to SDS-PAGE and immunoblotting for phos-
photyrosine, activated ERK2, phospho-MEK1, phospho-JNK, or other
epitopes. Antibody binding was detected using the ECL system and Hy-
perfilm x-ray film.
 
ERK Kinase Assay
 
ERK2 activity was assayed using Elk-1 fusion protein as a substrate pur-
chased from New England Biolabs, Inc. We confirmed that Elk-1 was
comparable to MBP as a substrate of ERK2 in these cells. The assay proto-
col recommended by the manufacturer was used, except for an additional
two washes with the kinase buffer after three washes with the lysis buffer.
Immunocomplex bead pellets were suspended in 50 
 
m
 
l kinase buffer sup-
plemented with 200 
 
m
 
M ATP and 2 
 
m
 
g Elk-1 fusion protein. After incuba-
tion for 30 min at 30
 
8
 
C, the reactions were stopped by adding SDS sample
buffer and heating the samples for 5 min at 100
 
8
 
C. Homogenates were
subjected to SDS-PAGE and immunoblotting for anti-phospho-Elk-1.
The phosphorylated substrate bands were quantitated by densitometry us-
ing NIH Image software. ERK2 activity was also assayed as described
(Miyamoto et al., 1996) using MBP as a substrate. Radioactivity in gel
slices from each sample was determined with a liquid scintillation counter.
 
Jun Kinase Assay
 
Phosphorylation of c-Jun NH
 
2
 
-terminal kinase (JNK) was evaluated using
anti-phospho-JNK monoclonal antibodies. Subconfluent cells were washed
once with PBS and were then exposed to 200 mJ/cm
 
2
 
 of UV light using a
Stratalinker UV Crosslinker (Stratagene, La Jolla, CA) followed by incu-
bation for 1 h at 37
 
8
 
C. Cells were lysed as described above.
 
Akt Phosphorylation Assay
 
For assaying Akt phosphorylation levels, we selected transfected cells us-
ing puromycin. Cotransfections of various plasmids with a puromycin-
resistance plasmid were performed as described above, and at 24 h after
transfection cells were subcultured at a 1:2 dilution and maintained for 3 d
in culture media containing puromycin (800 ng/ml). After 3 d selection,
surviving cells were detached and replated in 60-mm dishes (3 
 
3
 
 10
 
5
 
 cells/
dish) and cultured overnight in the absence of puromycin in regular cul-
ture media. The subconfluent cells were then cultured in media containing
0.2% FBS overnight. After PDGF treatment as indicated, the cells were
rinsed with cold PBS and homogenized in 300 
 
m
 
l lysis buffer. The cell ho-
mogenates were subjected to SDS-PAGE and immunoblotting for anti-
phospho-Akt or total Akt.
 
Ras GDP/GTP Exchange Assay
 
Levels of GTP-Ras were measured by labeling selected cells for 2 h in
phosphate-free media in the presence of 0.5 mCi/ml 
 
32
 
P-phosphate. The
selected cells as described above, were then incubated in serum-free and
phosphate-free medium with 0.1% BSA (lipid ultra-free) for 18 h, and
then labeled with 
 
32
 
P-phosphate at 0.5 mCi/ml for 2 h. After EGF treat-
ment as indicated, the cells were rinsed with cold PBS, and homogenized
 
in 500 
 
m
 
l lysis buffer (50 mM Tris, pH 7.5, 20 mM MgCl
 
2
 
, 150 mM NaCl,
0.5% NP40, 1 mM sodium vanadate, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupep-
tin, and 1 mM phenylmethylsulfonyl fluoride). The cell extracts were clar-
ified by centrifugation at 15,000 rpm (16,000 
 
g
 
) for 20 min, and then incu-
bated with 20 
 
m
 
l anti-H-ras coupled to Sepharose beads for 1 h. After
three washes with lysis buffer containing NaCl increased to a concentra-
tion of 500 mM, and two washes with 20 mM Tris, pH 7.5, 20 mM MgCl
 
2
 
,
500 mM NaCl, the sedimented beads were resuspended in 10 
 
m
 
l of 1 M
KH
 
2
 
PO
 
4
 
, pH 7.8, 5 mM EDTA plus 10 
 
m
 
l methanol, and then heated for 2
min at 68
 
8
 
C. After brief centrifugation, the supernatant solutions were an-
alyzed by thin layer chromatography on cellulose PEI-F plates in the pres-
ence of 1 M KH
 
2
 
PO
 
4
 
, pH 3.5. The plates were air dried and exposed to
x-ray film. The spots corresponding to GDP and GTP were quantitated by
excising the spots and scintillation counting.
 
Immunofluorescence Microscopy
 
12-mm glass coverslips were incubated with PBS containing 10 
 
m
 
g/ml FN
overnight at 4
 
8
 
C. The coverslips were blocked with 10 mg/ml BSA for an
additional 1 h at 37
 
8
 
C. Suspended cells treated as described above were al-
lowed to spread for 10 min in DME containing 1% BSA, fixed with 4%
paraformaldehyde, permeabilized with 0.5% Triton X-100 in PBS for 5
min, and then incubated with 4% paraformaldehyde in PBS for an addi-
tional 20 min. Focal adhesion formation was visualized by incubating first
with mouse anti-paxillin monoclonal antibody, and then with Cy-3Ðconju-
gated goat antibody to mouse immunoglobulin G.
 
Results
 
PTEN Inhibition of MAP Kinase Activation Stimulated 
by Fibronectin
 
Although it is now well-established that PTEN is fre-
quently deleted or mutated in a variety of tumors and tu-
mor cell lines including glioblastomas, the biological func-
tions of PTEN are poorly understood. Because we found
recently that PTEN can help to regulate integrin-depen-
dent cell spreading and focal adhesion formation (Tamura
et al., 1998), we examined integrin-mediated signaling
pathways. We measured the kinetics of ERK activation
stimulated by adhesion to fibronectin in U-87MG, a glio-
blastoma cell line missing PTEN protein due to a frame-
shift mutation (Li et al., 1997; Steck et al., 1997). Within 10
min after plating on fibronectin, approximately twofold in-
creases in MAP kinase activation were detected as mea-
sured by increased phosphorylation of the ERK substrate
Elk-1 in nontransfected and control cells transfected with
GFP plasmid without insert (Fig. 1 
 
A
 
).
In contrast, reconstitution of full-length wild-type PTEN-
GFP to levels 1Ð1.5 times the level in human fibroblasts
(confirmed by immunoblotting using polyclonal anti-
PTEN antibody; data not shown), resulted in suppression
of MAP kinase activation, such that there was no increase
in Elk-1 phosphorylation at 10 min, and sharply decreased
MAP kinase activity within 30 min as compared with con-
trols (Fig. 1, 
 
A
 
 and 
 
C
 
). The differences were significant at
the
 
 P 
 
, 
 
0.0001 level. Conversely, reduction of endogenous
PTEN levels by anti-sense RNA expression in NIH 3T3
cells (Tamura et al., 1998) resulted in a 1.4 
 
6
 
 0.2-fold in-
crease in MAP kinase activation (difference significant at
the
 
 P 
 
, 
 
0.05 level). This result supports the notion that
PTEN normally acts as a brake or suppressor of MAP ki-
nase activation. These findings were confirmed by direct
examination of ERK2 phosphorylation by immunoblot-
ting with phospho-ERK2 antibody, which identifies the
characteristic phosphorylation of activated ERK2 (Fig. 1 
The Journal of Cell Biology, Volume 143, 1998 1378
 
B
 
). The inhibition of MAP kinase activation after PTEN
expression was not accompanied by any change in cell via-
bility (
 
z
 
95% viability by trypan blue assay with or without
PTEN expression).
 
Effects of PTEN on Activation of MAP Kinase Kinase, 
JNK, or Akt
 
It has been reported that PTEN cannot dephosphorylate
isolated, activated ERK2 in vitro (Myers et al., 1997). We
examined whether PTEN affects the FN-stimulated phos-
phorylation level of MAP kinase kinase 1 (MEK1), which
is the component immediately upstream of ERK in the
Ras/ERK classic signaling pathway. We performed cotrans-
fections of GFP or GFP-PTEN with wild-type HA-MEK1,
immunoprecipitated homogenates with anti-HA antibody,
and then immunoblotted with anti-phospho-MEK1, which
recognizes only activated MEK1/2. The increased phos-
phorylation of MEK1 stimulated by FN was significantly
inhibited in GFP-PTEN expressing cells as compared with
cells expressed GFP tag only (Fig. 2 
 
A
 
). Previous experi-
ments have indicated that growth suppression and inhibi-
tion of integrin-mediated spreading and focal adhesion
formation in glioma cells requires a functional PTEN phos-
phatase catalytic domain (Furnari et al., 1997; Tamura et
al., 1998). As shown in Fig. 2 
 
A
 
, the pattern of induction of
MEK1 phosphorylation in cells transfected with the PTEN
phosphatase-inactive mutant C124A was the same as con-
trols without insert. This result demonstrates a similar re-
quirement for the PTEN phosphatase domain in its down-
modulation of MAP kinase activation.
In contrast to the effects of PTEN on ERK activation,
there were no significant effects on JNK activation after
stimulation by UV irradiation (Fig. 2 
 
B
 
) or Akt phosphor-
ylation (a target of phosphatidylinositol 3
 
9
 
-kinase) stimu-
lated by PDGF (Fig. 2 
 
C
 
). Identical induced patterns of
JNK phosphorylation were observed in all three transient
transfectants, including wild-type PTEN and the C124A
mutant (Fig. 2 
 
B
 
). Under all conditions, an additional high-
molecular mass band was observed by anti-HA-JNK1
staining, which may represent additional phosphorylation
independent of the sites evaluated by the anti-phospho-
JNK antibody (which recognizes phosphorylated Ser 63
and Ser 73); however, again no differences levels of this
band due to PTEN were observed (Fig. 2 
 
B
 
). For examin-
ing Akt phosphorylation levels, we performed cotransfec-
tion of GFP or GFP-PTEN with a puromycin resistance
plasmid. U-87MG cells were cotransfected with GFP vec-
tor or GFP-PTEN and a puromycin resistance plasmid,
and selected using puromycin for 3 d. This selection for
transient transfectants resulted in 
 
z
 
90% positive cells ex-
pressing GFP or GFP-PTEN as determined by fluores-
cence microscopy. As shown in Fig. 2 
 
C
 
, PTEN expression
had no detectable effect on Akt phosphorylation stimu-
lated by PDGF.
 
MAP Kinase Activation by Growth Factors Is Also 
Blocked by PTEN Expression
 
Both integrins and growth factors can stimulate ERK acti-
vation. DTBRG-05MG glioma cells expressing EGF but
Figure 1. PTEN inhibition of
ERK2 activation by adhesion
to FN. U-87MG cells were
transiently cotransfected
with HA-ERK2 and either
GFP or GFP-PTEN. 24 h af-
ter transfection, cells were
serum-restricted overnight
in 0.2% FBS. Cells were de-
tached and incubated in se-
rum-free medium for 30 min
at 378C as described under
Materials and Methods. The
cells were then either main-
tained in suspension (0 min)
or allowed to attach to FN-coated dishes at 378C for the indicated
times. Cell lysates were prepared and ERK2 activity was assayed
after immunoprecipitation as described under Materials and
Methods. (A) A representative example of ERK2 substrate phos-
phorylation assay: upper panels show phosphorylation levels of
the substrate Elk-1 stained by anti-phospho-Elk1 antibody and
lower panels indicate total quantities of HA-ERK2 stained by
anti-HA antibody. (B) Representative example of ERK2 phos-
phorylation assay: upper panels show phosphorylation levels of
ERK2 stained with anti-activated ERK antibody and lower pan-
els indicate total quantities of HA-ERK2 stained by anti-HA an-
tibody. (C) Quantitation of ERK2 as assayed by Elk-1 phos-
phorylation; the data shown represent the average of triplicate
samples 6 SD, with normalization of P-Elk-1 levels by HA-
ERK2 levels as determined by densitometric scanning of trans-
blot bands. s, GFP-expressing cells; d, GFP-PTEN-expressing
cells. *P , 0.0001 according to StudentÕs two-tailed t test.
Figure 2. Effects of PTEN
on phosphorylation of MEK1,
JNK1, and Akt. U-87MG
cells were transiently co-
transfected with GFP, wild-
type GFP-PTEN or C124A
mutant GFP-PTEN plus
either HA-MEK1 or HA-
JNK1. MEK1 phosphoryla-
tion was assayed using anti-
phospho-MEK antibody as
described for HA-ERK2 in
the legend to Fig. 1. For as-
saying JNK1 phosphorylation, transfectants were washed with
PBS and then exposed to 200 mJ/cm2 of UV irradiation followed
by incubation in complete culture medium for 1 h at 378C. Immu-
noprecipitations for HA-MEK1 and HA-JNK1 were performed
as described under Materials and Methods. For assaying Akt
phosphorylation, U-87MG cells were cotransfected with GFP
vector or GFP-PTEN with a puromycin resistance plasmid, and
selected using puromycin for 3 d. After PDGF treatment, the
cells were homogenated in lysis buffer as described under Materials
and Methods. Total homogenates were subjected to SDS-PAGE
and immunoblotting with anti-phospho-Akt. (A) Immunoprecip-
itated MEK1 phosphorylation stained by anti-phospho-MEK an-
tibody (top) and total HA-MEK1 stained by anti-HA antibody
(bottom). Note suppression of phospho-MEK1 phosphorylation
in wild-type PTEN-transfected cells. (B) JNK1 phosphorylation
stained by anti-phospho-JNK (top) and total HA-JNK1 stained
by anti-HA antibody (bottom). (C) Akt phosphorylation stained
by anti-phospho-Akt (top) and total Akt stained by anti-Akt
(bottom). Note lack of effects of PTEN cotransfection. 
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not PDGF receptors displayed ERK activation in re-
sponse to EGF, e.g., in control cells expressing GFP with-
out PTEN insert (Fig. 3 
 
A
 
). This activation was not
blocked by 50 nM wortmannin, a phosphatidylinositol
3
 
9
 
-kinase inhibitor (data not shown). However, EGF stim-
ulation of ERK activation was suppressed in PTEN-express-
ing cells (Fig. 3 
 
A
 
). ERK2 activity was assayed using MBP
as a substrate (Fig. 3 
 
B,
 
 
 
a
 
). The differences between effects
of EGF in cells that expressed wild-type PTEN versus mu-
tant PTEN were significant at the P , 0.0001 level (Fig. 3
B, b). PTEN also inhibited MEK1 phosphorylation stimu-
lated by either PDGF or FBS in U-87MG cells (Fig. 3 C).
Similarly, PTEN was found to inhibit MEK1 phosphoryla-
tion in DTBRG-05MG cells, as well as ERK activation af-
ter EGF stimulation in U-87MG cells (data not shown).
Taken together, these results suggested that PTEN might
block the MAP kinase pathway at some point upstream of
MEK that might be common to both integrin- and growth
factorÐmediated signaling pathways.
PTEN Does Not Inhibit EGF Receptor Phosphorylation
Integrin cooperation with growth factors can include
marked changes in the state of growth factor receptor au-
tophosphorylation (Cybulsky et al., 1994; Miyamoto et al.,
1996). Therefore, we examined for PTEN regulation of
EGF receptor phosphorylation levels. Interestingly, PTEN
expression had no detectable effect on EGF receptor au-
tophosphorylation stimulated by EGF in the three trans-
fectant glioma cell lines. As shown in Fig. 4, EGF stimula-
tion in U-87MG cells expressing wild-type PTEN had the
same levels of receptor phosphorylation as in control cells
or in those transfected with mutant PTEN. We compared
the effects of PTEN on FAK phosphorylation levels in
these same cell lines, since we recently found that PTEN
dephosphorylates FAK in vivo and in vitro and inhibits
FAK phosphorylation stimulated by FN (Tamura et al.,
1998). In this study, we observed that wild-type PTEN
inhibited FAK phosphorylation stimulated by EGF,
whereas phosphatase-inactive mutant PTEN permitted
the induction of FAK phosphorylation (Fig. 4).
PTEN Inhibition of Ras Activation
Ras has been suggested as an initial component in com-
mon between integrin- and growth factor-mediated MAP
kinase signaling pathways. Therefore, we speculated that
the ability of PTEN inhibit both integrin- and growth fac-
torÐmediated MAP kinase signaling pathways might be
due to PTEN inhibiting Ras activation. We tested for ef-
fects on activation in the EGF pathway by examining Ras
GTP loading in EGF-stimulated cells. As shown in Fig. 5,
transfection with GFP tag or mutant GFP-PTEN still per-
mitted substantial increases in GTP loading of Ras by a
factor of 2.1Ð2.6-fold over nonstimulated controls. How-
ever, cells transfected with wild-type GFP-PTEN were un-
able to generate significant increases in GTP loading of
Ras over controls after EGF stimulation (Fig. 5). The dif-
ferences between effects of EGF in cells that expressed
wild-type GFP-PTEN and GFP tag or mutant GFP-PTEN
were significant at the P , 0.0001 level. We also per-
formed cotransfection of wild-type GFP-PTEN with con-
stitutively activated H-Ras, and found that PTEN could
not block its ability to induce ERK2 phosphorylation
(data not shown). These results identify the initial Ras ac-
tivation step as an upstream source of PTEN inhibition of
MAP kinase activation.
PTEN Inhibits Shc phosphorylation and
Grb2 Recruitment
The adapter protein Shc has been implicated in the Ras
signaling pathway in growth factor-stimulated cells by vir-
tue of its association with the Grb2 adapter molecule. In
stimulated cells, Shc binds to the activated growth factor
Figure 3. Effects of PTEN
on MAP kinase activation
stimulated by growth fac-
tors. Cells were cotransfected
with GFP or GFP-PTEN
with HA-ERK2 (A and B) or
HA-MEK1 (C), then were
switched to culture in 0.2%
serum at 24 h after transfec-
tion. The serum-restricted
cells were then incubated 10
min with EGF (A, DBTRG-
05MG cells; B, U-87MG) or
with PDGF or 10% FBS (C,
U-87MG cells). Cell lysates
were prepared and equal
protein concentrations were
analyzed by immunoblotting
as described under Materials
and Methods. Upper panels
show phosphorylation levels using anti-phospho-ERK (A) or
anti-phospho-MEK (C). Lower panels show relative quantities of
total protein as determined by anti-HA immunoblotting (A, B a,
C). ERK2 activity after EGF stimulation was examined using
MBP as a substrate (B a). (B b) Quantitation of ERK2 activity by
scintillation counting of incorporated radioactivity; the data are
shown as fold increases in 32P incorporation into MBP compared
with the unstimulated control, which is taken as 1.0. Data repre-
sent means 6 SD of three experiments. *P , 0.0001 compared
with EGF stimulation in cells transfected with GFP or GFP-
PTEN with the C124A mutation.
Figure 4. Effects of PTEN
on EGF receptor and FAK
phosphorylation. U-87MG
cells were cotransfected with
GFP, wild-type GFP-PTEN,
or phosphatase-inactivated
mutant GFP-PTEN and a
puromycin-resistance plas-
mid. Transfectant cells were
selected for 3 d using puro-
mycin as described under
Materials and Methods. Im-
munoprecipitations were car-
ried out with anti-EGFR
and anti-FAK. Upper panel shows phosphorylation of EGF re-
ceptor stained by anti-phosphotyrosine (monoclonal antibody
RC20) and the middle panel indicates total EGF receptor. Lower
panel shows FAK phosphorylation levels.The Journal of Cell Biology, Volume 143, 1998 1380
receptor and becomes phosphorylated. Upon phosphory-
lation, Shc interacts with the SH2 domain of Grb2 and
functions as an alternative docking site for the Grb2-Sos
complex (Rozakis-Adcock et al., 1992; Pawson, 1995). As
shown in Fig. 6, Shc has three isoforms of 66, 52, and 46 kD,
which derive from differential translation initiation at
three ATG sites (Migliaccio et al., 1997). U-87MG cells
expressing wild-type PTEN showed substantial suppres-
sion of Shc phosphorylation after EGF stimulation (espe-
cially the 52-kD isoform, which showed a 61 6 9% reduc-
tion compared with control Shc phosphorylation; Fig. 6,
upper middle). Consistent with this effect, recruitment of
Grb2 was also downregulated by PTEN expression (Fig. 6,
lower middle). However, quantities of EGF receptor asso-
ciated with Shc (Fig. 6, top) showed no detectable differ-
ences between control and PTEN-expressing cells, consis-
tent with the finding that PTEN does not inhibit EGF
receptor phosphorylation. PTEN also inhibited Shc phos-
phorylation stimulated by FN binding to integrins (data
not shown).
Experimental Activation of MAP Kinase Partially 
Rescues Cell Spreading Impaired by PTEN Expression
To investigate the role of MAP kinase activation in a puta-
tive cell biological function of PTEN, we used a transient
cotransfection assay that permitted restoration of MAP ki-
nase activation impaired by PTEN expression using con-
stitutively activated MEK1, a downstream component of
the Ras/ERK signaling pathway. Our recent studies had
indicated that PTEN affects cell spreading on FN by hu-
man fibroblasts, as well as by U-87MG and DBTRG-
05MG glioma cell lines, though the duration of PTEN ef-
fects differed. In human foreskin fibroblasts, the effect on
spreading was maximal at 20Ð30 min after adhesion to fi-
bronectin, but diminished after 2 h. However, clear inhibi-
tion of cell spreading could be observed even after 18 h in
DBTRG-05MG cells (Tamura et al., 1998). These cell-
type differences may be explained by the fact that human
fibroblasts express endogenous PTEN, whereas U-87MG
and DBTRG-05MG cells do not express the protein due to
mutations. The morphology of PTEN-expressing U-87MG
cells includes thin cell processes somewhat resembling
these of oligodendroglial cells (Tamura et al., 1998). In this
study, we compared cell spreading at 10 min in three
glioma cell lines: U-87MG, DBTRG-05MG and U-373MG;
FN stimulation of ERK activation is maximal at this time
point in these cells. Overexpression of constitutively acti-
vated MEK1 was accompanied by two- to fivefold in-
creases in ERK activity compared with wild-type MEK1
stimulated by FN. Of particular interest, cotransfection of
constitutively activated MEK1 with wild-type PTEN par-
tially rescued cell spreading and focal contact formation.
As shown in Fig. 7 A, the enhancement of focal contact
formation was apparent by paxillin staining. The propor-
tion of cells capable of spreading increased by .65%, ris-
ing from a value of 31% of total cells spread with PTEN
alone to 52% in cells with PTEN plus activated MEK1
(Fig. 7 B). The differences in cell spreading were signifi-
cant at the P , 0.01 level. In contrast, parallel cooverex-
pression of constitutively activated MEK1 with the PTEN
controls of GFP alone or mutant GFP-PTEN had no effect
on cell spreading and focal contact formation (data not
shown). Because we had previously shown that FAK over-
expression could also partially rescue the cell spreading re-
sponse, we performed a triple transfection experiment
combining PTEN, FAK, and activated MEK1. The results
showed no further rescue of cell spreading, with the per-
centages of cell spreading when cotransfected with PTEN
as follows: active MEK1 5 50 6 3%; HA-FAK 5 52 6
5%; and active MEK1 1 HA-FAK 5 49 6 6%. This result
strongly suggests a linear rather than parallel biological
pathway, consistent with a downstream effect of PTEN on
MEK and ERK through FAK for cell spreading.
Discussion
Many recent studies have established that the PTEN gene
Figure  5. Inhibition of Ras
activation by wild-type
PTEN. Puromycin-selected
cells were prelabeled with
32P-phosphate, then exposed
to 10 ng/ml EGF for 10 min.
Cell extracts were immuno-
precipitated with specific
anti-H-Ras antibody, and
bound GTP and GDP were
resolved by thin layer chro-
matography as described un-
der Materials and Methods.
(A) A representative exam-
ple of separation patterns of
GTP and GDP on a PEI-F
cellulose plate for cells trans-
fected by GFP (vector con-
trol), wild-type GFP-PTEN,
or GFP-PTEN with the
C124A mutation. (B) Quan-
titative evaluation of Ras ac-
tivation presented as the
fold increase in GTP/GDP
ratio compared with unstim-
ulated control, which is taken
as 1.0. Data represent the means 6 SD of three experiments.
*P , 0.0001 compared with its control using StudentÕs t test.
Figure  6. Inhibition of Shc
phosphorylation by PTEN.
Puromycin-selected transfec-
tant cells were exposed to 10
ng/ml EGF for 10 min. Cell
extracts were immunoprecip-
itated with monoclonal anti-
Shc antibody. Phosphoryla-
tion of Shc was detected by
anti-phosphotyrosine (mono-
clonal antibody RC 20; upper
middle panel), and other pro-
teins associated with Shc were detected using polyclonal anti-
EGF receptor (top) or Grb2 (lower middle panel) antibodies. To-
tal Shc levels were evaluated by immunoblotting using polyclonal
anti-Shc antibody (bottom).Gu et al. PTEN Inhibits Map Kinase Signaling Pathways 1381
is deleted or mutated in a wide variety of tumor tissues
and tumor cell lines, as well as in two genetic disorders
with predisposition to cancer (Kong et al., 1997; Li et al.,
1997; Liaw et al., 1997; Marsh et al., 1997; Nelen et al.,
1997; Steck et al., 1997). Furthermore, transfected PTEN
suppresses cell growth and tumorigenicity in glioblastoma
cell lines (Furnari et al., 1997; Cheney et al., 1998). There-
fore, PTEN is considered a major new tumor suppressor.
One theoretically attractive site of action of PTEN
might be on the MAP kinases, which comprise central cel-
lular regulatory pathways. In this report, we tested for ef-
fects of PTEN on integrin- and growth factor-mediated
MAP kinase signaling. Our major findings are summarized
in Fig. 8, and include the following: (a) activation of the
ERK type of MAP kinase is inhibited by PTEN expression
in cells lacking the protein, whether stimulated by integrin
ligation or a growth factor, yet the JNK/SAPK MAP ki-
nase pathway and Akt are unaffected; (b) expression of
anti-sense PTEN to reduce PTEN in cells that normally
express this protein results in ERK activation; (c) up-
stream MEK and Ras activation and Shc phosphorylation
are inhibited, but EGF receptor phosphorylation is not
affected; (d) the inhibition of Ras can be overcome by
expression of activated Ras; and (e) overexpression of an
activated downstream component of the pathway, MEK1,
can antagonize the biological effects of PTEN on cell spread-
ing and focal contact formation. Our results strongly sug-
gest that down-regulation of the Ras/MAP kinase pathway
is an important function of the PTEN tumor suppressor
gene in its cell biological functions.
Many studies have established the essential role of the
MAP kinase pathway in cellular transformation and cell
cycle regulation. Mutant oncogenic forms of upstream sig-
naling components such as Ras, Raf-1, and G proteins
have been found in malignant cells (Bishop, 1991). Con-
versely, inhibition of the MAP kinase pathway blocks c-RasÐ
and v-MosÐdependent cell transformation, and inhibits
cell growth, cell adhesion, and spreading (Pages et al.,
1993; Cowley et al., 1994; Okazaki and Sagata, 1995;
Hughes et al., 1997; Whalen et al., 1997). Consistent with
some of these observations, in this study increased MAP
kinase activation induced by constitutively activated
MEK1 could partially rescue cell spreading; it had, how-
ever, no significant effects on cell growth (data not
shown). These findings indicate that the MAP kinase path-
way is not the only pathway affected by PTEN.
Two substrates of PTEN have been identified recently,
focal adhesion kinase (FAK) and certain phosphoinositol
lipids (Maehama and Dixon, 1998; Tamura et al., 1998).
The role of FAK in integrin-mediated MAP kinase activa-
tion is controversial (Schlaepfer et al., 1994; Richardson
and Parsons, 1995; Wary et al., 1996; Lin et al., 1997;
Figure  7. Effects of constitu-
tively activated MEK1 on PTEN-
expressing cells. U-87MG cells
were cotransfected with GFP,
wild-type GFP-PTEN or phos-
phatase mutant GFP-PTEN,
with or without constitutively
activated MEK1 or dominant-
negative MEK1, and then al-
lowed to attach to FN-coated
coverslips for 10 min as de-
scribed under Materials and
Methods. (A) A representative
example of paxillin staining indi-
cated by arrowheads; the green fluorescence-expressing cells are
marked by open arrows; (a) GFP tag; (b) C124A mutant GFP-
PTEN; (c) wild-type GFP-PTEN; (d) GFP-PTEN with dominant
negative MEK1; (e) GFP-PTEN with constitutively activated
MEK1. Localization in the thick central portion of poorly spread
cells does not represent specific staining; this region is so much
thicker than spreading cytoplasm that normal low-level, nonspe-
cific staining appears brighter. The same immunofluorescence ar-
tifact is seen with nonimmune antibody in poorly spread cells
(data not shown). Bar, 10 mm. (B) Cell spreading assay showing
the percentage of cells that had spread at 10 min as determined
by paxillin staining; the data are means 6 SD of four experi-
ments; 100 cells were counted for each experiment. *P , 0.01
versus cells transfected with GFP-PTEN only, or versus GFP-
PTEN plus dominant negative MEK1. DN, dominant negative;
Act, constitutively activated MEK1.
Figure 8. Working model of
the PTEN regulatory net-
work. Integrins and growth
factors can separately stimu-
late the Ras/ERK/MAP ki-
nase pathway or function
collaboratively. Integrin re-
ceptor engagement with FN
stimulates FAK, Shc and c-Src,
and they activate the path-
way as described (Schlaepfer
et al., 1998). Growth factors
can activate the pathway
through autophosphoryla-
tion of growth factor receptors. PTEN reduces Shc phosphoryla-
tion and its interaction with Grb2, as well as the downstream Ras/
ERK common MAP kinase pathway for integrin- and growth fac-
torÐmediated signaling, and then affects cell spreading and focal
contact formation. Activated MEK1 can partially reverse the lat-
ter effects of PTEN.The Journal of Cell Biology, Volume 143, 1998 1382
Schlaepfer and Hunter, 1997; Wary et al., 1998), but it ap-
pears to be one of several possible pathways for enhancing
the binding of Grb2, leading to the formation of signaling
complexes that promote activation of the Ras signaling
pathway (Schlaepfer et al., 1994). FAK is probably not,
however, an intermediary in EGF growth factor receptor
stimulation. In contrast to FAK, Shc is a more plausible ef-
fector for growth factor-mediated MAP kinase activation.
Several lines of evidence suggest that Shc-Grb2 associa-
tion after growth factor or integrin stimulation is involved
in Ras activation (Rozakis-Adcock et al., 1992; Pronk et al.,
1994; Wary et al., 1998). It will be interesting to investigate
the mechanisms by which PTEN inhibits Shc phosphoryla-
tion.
Recently, it has been reported that PTEN dephosphory-
lates phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3),
which is a product of phosphoinositide 39-kinase (PI 3-kinase),
specifically at position 3 on the inositol ring (Maehama
and Dixon, 1998). However, EGF receptor signaling does
not appear to require PI 3-kinase activation (King et al.,
1997 and data not shown), making it unlikely that the ef-
fects of PTEN on MAP kinase activation by this pathway
is via effects on phosphoinositides. Moreover, even though
PTEN inhibits MAP kinase activation by PDGF, it does
not affect PDGF-induced phosphorylation of Akt, a target
of PI 3-kinase. Integrin activation of inositol lipid signaling
appears to feed into the Ras/MAP kinase pathway at Raf
(King et al., 1997). In the present study, however, expres-
sion of an upstream component, activated Ras, was suffi-
cient to overcome the effect of PTEN on MAP kinase acti-
vation. Taken collectively, these findings suggest that the
effects of PTEN on MAP kinase signaling in these cells is
not via effects on phosphoinositides, but is instead through
effects on Ras signaling.
PTEN consequently has complex but important effects
on signaling and cell biological processes. It can down-
modulate Ras-mediated MAP kinase activation from in-
tegrins and growth factors (this study), phosphoinositide
signaling, FAK and p130Cas tyrosine phosphorylation,
Shc tyrosine phosphorylation and Grb2 recruitment (this
study), focal adhesion and actin cytoskeletal organization,
cell proliferation, and cell migration (Furnari et al., 1997;
Cheney et al., 1998; Maehama and Dixon, 1998; Tamura
et al., 1998). These pleiotropic but selective effects are
probably due to specific actions of its phosphatase, since
the biological actions examined required an intact phos-
phatase domain. PTEN is thus a new regulator of a specific
subset of important cell biological functions. Overall, our
results suggest key sites of action of PTEN on (a) Shc and
its interaction with the adapter protein Grb2 and (b) focal
adhesion kinase. PTEN expression results in dephos-
phorylation of these two molecules, accompanied by inhi-
bition of Ras activation, followed by further downstream
effects targeting the ERK pathway of MAP kinase signal-
ing, but without affecting JNK or Akt signaling.
Received for publication 21 July 1998 and in revised form 21 September
1998.
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